Skip to main content
Erschienen in: Endocrine 3/2011

01.12.2011 | Original Article

Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy

verfasst von: Yun-ze Xu, Yu Zhu, Zhou-jun Shen, Jia-yan Sheng, Hong-chao He, Gui Ma, Yi-cheng Qi, Ju-ping Zhao, Yu-xuan Wu, Wen-bin Rui, Qing Wei, Wen-long Zhou, Xin Xie, Guang Ning

Erschienen in: Endocrine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to determine the correlation between human adrenocortical carcinoma (ACC) and the proteins involved in tumor angiogenesis, and to evaluate the angiogenic status of ACC. The expression of heparanase-1 (HPA-1), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor-2 (VEGFR-2) as well as microvessel density (MVD) were measured in a series of tissue samples from 44 human sporadic adrenocortical tumors by immunohistochemistry. These specimens were classified as adenomas (n = 20) and carcinomas (n = 24) according to the histological criteria defined by Weiss. A total of 22 of 24 (91.67%) malignant cases showed positive staining for HPA-1 and 3 of 20 (15%) benign cases showed positive, the difference of HPA-1 expression between ACA and ACC was statistically significant (P < 0.001). Similarly, VEGF staining was seen in 70.83% (17/24) of the malignant cases versus 25% (5/20) of the benign, the difference of VEGF expression among two groups was statistically significant (P = 0.002). VEGFR-2 expressed highly in the ACC group (79.17%, 19/24) and lowly in the benign group (25%, 5/20), the two groups had extremely significant difference (P < 0.001). Malignant cases showed higher MVD compared to benign tumors (84.70 ± 12.44 vs. 21.05 ± 8.07, P < 0.001). HPA-1 and VEGF expression were positively correlated with MVD in all specimens (r_s = 0.812, P = 0.001; r_s = 0.834, P < 0.001). In conclusion, these results suggest that angiogenesis of human ACC maybe mediated by these proteins and they could represent selective targets for the molecularly targeted treatments of ACC.
Literatur
1.
Zurück zum Zitat M. Fassnacht, R. Libe, M. Kroiss et al., Adrenocortical carcinoma: a clinician’s update. Nat. Rev. Endocrinol. 7, 323–335 (2011)PubMedCrossRef M. Fassnacht, R. Libe, M. Kroiss et al., Adrenocortical carcinoma: a clinician’s update. Nat. Rev. Endocrinol. 7, 323–335 (2011)PubMedCrossRef
2.
Zurück zum Zitat B. Allolio, M. Fassnacht, Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91, 2027–2037 (2006)PubMedCrossRef B. Allolio, M. Fassnacht, Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91, 2027–2037 (2006)PubMedCrossRef
3.
Zurück zum Zitat M. Fassnacht, B. Allolio, What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin. Endocrinol. (Oxf) 73, 561–565 (2010)CrossRef M. Fassnacht, B. Allolio, What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin. Endocrinol. (Oxf) 73, 561–565 (2010)CrossRef
4.
Zurück zum Zitat A. Berruti, M. Fassnacht, E. Baudin et al., Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J. Clin. Oncol. 28, 401–403 (2010)CrossRef A. Berruti, M. Fassnacht, E. Baudin et al., Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J. Clin. Oncol. 28, 401–403 (2010)CrossRef
5.
Zurück zum Zitat D.E. Schteingart, G.M. Doherty, P.G. Gauger et al., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12, 667–680 (2005)PubMedCrossRef D.E. Schteingart, G.M. Doherty, P.G. Gauger et al., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12, 667–680 (2005)PubMedCrossRef
6.
Zurück zum Zitat I.J. Fidler, L.M. Ellis, The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185–188 (1994)PubMedCrossRef I.J. Fidler, L.M. Ellis, The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185–188 (1994)PubMedCrossRef
7.
Zurück zum Zitat N. Ferrara, Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physiol. 280, C1358–C1366 (2001)PubMed N. Ferrara, Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physiol. 280, C1358–C1366 (2001)PubMed
8.
Zurück zum Zitat N. Weidner, Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19 (1995)PubMed N. Weidner, Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19 (1995)PubMed
9.
Zurück zum Zitat H. Sawai, Y. Okada, H. Funahashi et al., Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J. Surg. Res. 144, 117–123 (2008)PubMedCrossRef H. Sawai, Y. Okada, H. Funahashi et al., Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J. Surg. Res. 144, 117–123 (2008)PubMedCrossRef
10.
Zurück zum Zitat M. Bernfield, M. Gotte, P.W. Park et al., Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729–777 (1999)PubMedCrossRef M. Bernfield, M. Gotte, P.W. Park et al., Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729–777 (1999)PubMedCrossRef
11.
Zurück zum Zitat C.R. Parish, C. Freeman, M.D. Hulett, Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471, M99–M108 (2001)PubMed C.R. Parish, C. Freeman, M.D. Hulett, Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471, M99–M108 (2001)PubMed
12.
Zurück zum Zitat I. Vlodavsky, Y. Friedmann, Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341–347 (2001)PubMed I. Vlodavsky, Y. Friedmann, Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341–347 (2001)PubMed
13.
Zurück zum Zitat H. Wang, J.L. Si, X.Z. Zhang et al., Expression and clinical significance of syndecan-1 mRNA and HPA-1 mRNA in colorectal cancer detected with real-time fluorescent quantitative polymerase chain reaction. Chin. J. Cancer 29, 288–293 (2010)PubMed H. Wang, J.L. Si, X.Z. Zhang et al., Expression and clinical significance of syndecan-1 mRNA and HPA-1 mRNA in colorectal cancer detected with real-time fluorescent quantitative polymerase chain reaction. Chin. J. Cancer 29, 288–293 (2010)PubMed
14.
Zurück zum Zitat K.S. Rohrberg, B.G. Skov, U. Lassen et al., Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomark. 7, 141–151 (2010)PubMed K.S. Rohrberg, B.G. Skov, U. Lassen et al., Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomark. 7, 141–151 (2010)PubMed
15.
Zurück zum Zitat U. Yildirim, H. Erdem, A. Kayikci et al., Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density. J. Int. Med. Res. 38, 1689–1699 (2010)PubMed U. Yildirim, H. Erdem, A. Kayikci et al., Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density. J. Int. Med. Res. 38, 1689–1699 (2010)PubMed
16.
Zurück zum Zitat J.C. Yang, L. Haworth, R.M. Sherry et al., A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003)PubMedCrossRef J.C. Yang, L. Haworth, R.M. Sherry et al., A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003)PubMedCrossRef
17.
Zurück zum Zitat A. Sandler, R. Gray, M.C. Perry et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006)PubMedCrossRef A. Sandler, R. Gray, M.C. Perry et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006)PubMedCrossRef
18.
Zurück zum Zitat B. Ramaswamy, A.D. Elias, N.T. Kelbick et al., Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12, 3124–3129 (2006)PubMedCrossRef B. Ramaswamy, A.D. Elias, N.T. Kelbick et al., Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12, 3124–3129 (2006)PubMedCrossRef
19.
Zurück zum Zitat S. Wortmann, M. Quinkler, C. Ritter et al., Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol. 162, 349–356 (2010)PubMedCrossRef S. Wortmann, M. Quinkler, C. Ritter et al., Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol. 162, 349–356 (2010)PubMedCrossRef
20.
Zurück zum Zitat L.M. Weiss, L.J. Medeiros Jr, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989)PubMedCrossRef L.M. Weiss, L.J. Medeiros Jr, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989)PubMedCrossRef
21.
Zurück zum Zitat R. Kouyama, K. Hiraishi, T. Sugiyama et al., Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma. Endocr. J. 2011 Apr 27. [Epub ahead of print] R. Kouyama, K. Hiraishi, T. Sugiyama et al., Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma. Endocr. J. 2011 Apr 27. [Epub ahead of print]
22.
Zurück zum Zitat Y. Kitadai, K. Haruma, T. Tokutomi et al., Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 4, 2195–2200 (1998)PubMed Y. Kitadai, K. Haruma, T. Tokutomi et al., Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 4, 2195–2200 (1998)PubMed
23.
Zurück zum Zitat Y. Zhu, H.C. He, F. Yuan et al., Heparanase-1 and cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas. Endocrine 38, 93–99 (2010)PubMedCrossRef Y. Zhu, H.C. He, F. Yuan et al., Heparanase-1 and cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas. Endocrine 38, 93–99 (2010)PubMedCrossRef
24.
Zurück zum Zitat I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009)PubMedCrossRef I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009)PubMedCrossRef
25.
Zurück zum Zitat I.G. Hermsen, M. Fassnacht, M. Terzolo et al., Plasma concentrations of o, p′DDD, o, p′DDA, and o, p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a Retrospective ENS@T Multicenter Study. J. Clin. Endocrinol. Metab. 96, 1844–1851 (2011)PubMedCrossRef I.G. Hermsen, M. Fassnacht, M. Terzolo et al., Plasma concentrations of o, p′DDD, o, p′DDA, and o, p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a Retrospective ENS@T Multicenter Study. J. Clin. Endocrinol. Metab. 96, 1844–1851 (2011)PubMedCrossRef
26.
Zurück zum Zitat M. Fassnacht, S. Johanssen, M. Quinkler et al., Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009)PubMedCrossRef M. Fassnacht, S. Johanssen, M. Quinkler et al., Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009)PubMedCrossRef
27.
Zurück zum Zitat T.J. Giordano, R. Kuick, T. Else et al., Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668–676 (2009)PubMedCrossRef T.J. Giordano, R. Kuick, T. Else et al., Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668–676 (2009)PubMedCrossRef
28.
Zurück zum Zitat A. de Reynies, G. Assie, D.S. Rickman et al., Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009)PubMedCrossRef A. de Reynies, G. Assie, D.S. Rickman et al., Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009)PubMedCrossRef
29.
Zurück zum Zitat J.B. Laforga, F.I. Aranda, Angiogenic index: a new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6, 103–107 (2000)PubMedCrossRef J.B. Laforga, F.I. Aranda, Angiogenic index: a new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6, 103–107 (2000)PubMedCrossRef
30.
Zurück zum Zitat S.J. Diaz-Cano, M. de Miguel, A. Blanes, H. Galera, H.J. Wolfe, Contribution of the microvessel network to the clonal and kinetic profiles of adrenal cortical proliferative lesions. Hum. Pathol. 32, 1232–1239 (2001)PubMedCrossRef S.J. Diaz-Cano, M. de Miguel, A. Blanes, H. Galera, H.J. Wolfe, Contribution of the microvessel network to the clonal and kinetic profiles of adrenal cortical proliferative lesions. Hum. Pathol. 32, 1232–1239 (2001)PubMedCrossRef
32.
Zurück zum Zitat S. Zacharieva, I. Atanassova, M. Orbetzova et al., Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur. J. Endocrinol. 150, 345–349 (2004)PubMedCrossRef S. Zacharieva, I. Atanassova, M. Orbetzova et al., Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur. J. Endocrinol. 150, 345–349 (2004)PubMedCrossRef
33.
Zurück zum Zitat F. de Fraipont, M. El Atifi, C. Gicquel et al., Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 85, 4734–4741 (2000)PubMedCrossRef F. de Fraipont, M. El Atifi, C. Gicquel et al., Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 85, 4734–4741 (2000)PubMedCrossRef
34.
Zurück zum Zitat M.D. Hulett, C. Freeman, B.J. Hamdorf et al., Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803–809 (1999)PubMedCrossRef M.D. Hulett, C. Freeman, B.J. Hamdorf et al., Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803–809 (1999)PubMedCrossRef
35.
Zurück zum Zitat K. Gohji, H. Hirano, M. Okamoto et al., Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95, 295–301 (2001)PubMedCrossRef K. Gohji, H. Hirano, M. Okamoto et al., Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95, 295–301 (2001)PubMedCrossRef
36.
Zurück zum Zitat M. Elkin, N. Ilan, R. Ishai-Michaeli et al., Heparanase as mediator of angiogenesis: mode of action. FASEB. J. 15, 1661–1663 (2001)PubMed M. Elkin, N. Ilan, R. Ishai-Michaeli et al., Heparanase as mediator of angiogenesis: mode of action. FASEB. J. 15, 1661–1663 (2001)PubMed
Metadaten
Titel
Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy
verfasst von
Yun-ze Xu
Yu Zhu
Zhou-jun Shen
Jia-yan Sheng
Hong-chao He
Gui Ma
Yi-cheng Qi
Ju-ping Zhao
Yu-xuan Wu
Wen-bin Rui
Qing Wei
Wen-long Zhou
Xin Xie
Guang Ning
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2011
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9502-1

Weitere Artikel der Ausgabe 3/2011

Endocrine 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.